Opinion|Videos|May 21, 2025
CABINET Trial: Results
Author(s)Thorvardur R. Halfdanarson, MD
A panelist discusses how the CABINET trial showed significant progression-free survival benefits for cabozantinib compared with placebo (particularly in pancreatic neuroendocrine tumors (NETs), why progression-free survival (PFS) is a meaningful end point for NETs, and that safety findings revealed familiar adverse effects requiring dose reductions in about two-thirds of patients.
Advertisement
Video content above is prompted by the following:
CABINET Trial Results
Key Themes:
- Progression-Free Survival (PFS) as Primary End Point:
- PFS is an agreed-upon end point by an NCI task force for NETs
- Appropriate due to generally longer overall survival in NETs compared with other metastatic solid tumors
- PFS serves as a surrogate for benefit and possibly overall survival
- Extrapancreatic Cohort Results:
- PFS: 8.4 months (cabozantinib) vs 3.9 months (placebo); statistically significant
- Overall survival: 21.9 months vs 19.7 months; not statistically significant
- 33% crossed over from placebo to cabozantinib
- Pancreatic Cohort Results:
- PFS: 13.8 months (cabozantinib) vs 4.4 months (placebo); more pronounced difference
- Overall survival: 40 months vs 31.1 months; not statistically significant
- 41% crossed over from placebo to cabozantinib
- Safety Profile:
- No new safety signals identified
- Two-thirds of patients required dose reduction
- Average daily dose was just under 40 mg per day in both cohorts
Notable Insights:
Dr Halfdanarson observed that the more pronounced PFS benefit in pancreatic NETs was not surprising, as these tumors have historically been responsive to VEGF-directed therapies like sunitinib.
Advertisement
Related to this article
The application is supported by the phase 3 SAFFRON trial, in which savolitinib plus osimertinib improved progression-free and overall survival vs chemotherapy.
Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
Published findings from the ASPEN-06 trial of evorpacept in previously treated HER2+ gastric cancers included exploratory analyses suggesting CD47 is a predictive biomarker for benefit with the targeted agent.
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.
The FDA communicated that the phase 2 IDeate-Lung01 results were not sufficient for an accelerated approval of I-DXd in small cell lung cancer.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Frontline CAR T and Bispecific Antibodies Are the Next Frontier in Myeloma
5